M. TERZİ Et Al. , "Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment," Nöropsikiyatri Arşivi , vol.60, no.1, pp.23-27, 2023
TERZİ, M. Et Al. 2023. Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment. Nöropsikiyatri Arşivi , vol.60, no.1 , 23-27.
TERZİ, M., HELVACI, E. M., şen, s., BOZ, C., CILINGIR, V., AKÇALI, A., ... Beckmann, Y.(2023). Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment. Nöropsikiyatri Arşivi , vol.60, no.1, 23-27.
TERZİ, Murat Et Al. "Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment," Nöropsikiyatri Arşivi , vol.60, no.1, 23-27, 2023
TERZİ, Murat Et Al. "Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment." Nöropsikiyatri Arşivi , vol.60, no.1, pp.23-27, 2023
TERZİ, M. Et Al. (2023) . "Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment." Nöropsikiyatri Arşivi , vol.60, no.1, pp.23-27.
@article{article, author={Murat TERZİ Et Al. }, title={Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment}, journal={Nöropsikiyatri Arşivi}, year=2023, pages={23-27} }